196 related articles for article (PubMed ID: 36282521)
21. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.
Gong C; Ruiz-Martinez A; Kimko H; Popel AS
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359653
[TBL] [Abstract][Full Text] [Related]
22. FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective.
Bai JPF; Schmidt BJ; Gadkar KG; Damian V; Earp JC; Friedrich C; van der Graaf PH; Madabushi R; Musante CJ; Naik K; Rogge M; Zhu H
AAPS J; 2021 Apr; 23(3):60. PubMed ID: 33931790
[TBL] [Abstract][Full Text] [Related]
23. Current practices for QSP model assessment: an IQ consortium survey.
Chan JR; Allen R; Boras B; Cabal A; Damian V; Gibbons FD; Gulati A; Hosseini I; Kearns JD; Saito R; Cucurull-Sanchez L; Selimkhanov J; Stein AM; Umehara K; Wang G; Wang W; Neves-Zaph S
J Pharmacokinet Pharmacodyn; 2022 Aug; ():1-13. PubMed ID: 35953664
[TBL] [Abstract][Full Text] [Related]
24. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T; Liao X; Cao Y
Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
Front Immunol; 2019; 10():924. PubMed ID: 31134058
[TBL] [Abstract][Full Text] [Related]
26. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
27. Development of and insights from systems pharmacology models of antibody-drug conjugates.
Lam I; Pilla Reddy V; Ball K; Arends RH; Mac Gabhann F
CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):967-990. PubMed ID: 35712824
[TBL] [Abstract][Full Text] [Related]
28. Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression.
McComb M; Blair RH; Lysy M; Ramanathan M
J Pharmacokinet Pharmacodyn; 2022 Feb; 49(1):65-79. PubMed ID: 34611796
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.
Helmlinger G; Sokolov V; Peskov K; Hallow KM; Kosinsky Y; Voronova V; Chu L; Yakovleva T; Azarov I; Kaschek D; Dolgun A; Schmidt H; Boulton DW; Penland RC
CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):380-395. PubMed ID: 31087533
[TBL] [Abstract][Full Text] [Related]
30. Integrative Pharmacology: Advancing Development of Effective Immunotherapies.
Tabrizi M; Zhang D; Ganti V; Azadi G
AAPS J; 2018 Apr; 20(4):66. PubMed ID: 29704129
[TBL] [Abstract][Full Text] [Related]
31. Dynamical systems analysis as an additional tool to inform treatment outcomes: The case study of a quantitative systems pharmacology model of immuno-oncology.
Balti A; Zugaj D; Fenneteau F; Tremblay PO; Nekka F
Chaos; 2021 Feb; 31(2):023124. PubMed ID: 33653032
[TBL] [Abstract][Full Text] [Related]
32. Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.
Ji Y; Sy SKB
Cancer Chemother Pharmacol; 2024 Apr; 93(4):273-293. PubMed ID: 38430307
[TBL] [Abstract][Full Text] [Related]
33. A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability.
Chung D; Bakshi S; van der Graaf PH
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986779
[TBL] [Abstract][Full Text] [Related]
34. Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration.
Bai JPF; Earp JC; Florian J; Madabushi R; Strauss DG; Wang Y; Zhu H
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1479-1484. PubMed ID: 34734497
[TBL] [Abstract][Full Text] [Related]
35. Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
Bradshaw EL; Spilker ME; Zang R; Bansal L; He H; Jones RDO; Le K; Penney M; Schuck E; Topp B; Tsai A; Xu C; Nijsen MJMA; Chan JR
CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):777-791. PubMed ID: 31535440
[TBL] [Abstract][Full Text] [Related]
36. Quantitative Systems Pharmacology and Machine Learning: A Match Made in Heaven or Hell?
Tindall MJ; Cucurull-Sanchez L; Mistry H; Yates JWT
J Pharmacol Exp Ther; 2023 Oct; 387(1):92-99. PubMed ID: 37652709
[TBL] [Abstract][Full Text] [Related]
37. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
Nijsen MJMA; Wu F; Bansal L; Bradshaw-Pierce E; Chan JR; Liederer BM; Mettetal JT; Schroeder P; Schuck E; Tsai A; Xu C; Chimalakonda A; Le K; Penney M; Topp B; Yamada A; Spilker ME
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):135-146. PubMed ID: 29349875
[TBL] [Abstract][Full Text] [Related]
38. A framework for simplification of quantitative systems pharmacology models in clinical pharmacology.
Derbalah A; Al-Sallami H; Hasegawa C; Gulati A; Duffull SB
Br J Clin Pharmacol; 2022 Feb; 88(4):1430-1440. PubMed ID: 32621550
[TBL] [Abstract][Full Text] [Related]
39. Boolean Modeling in Quantitative Systems Pharmacology: Challenges and Opportunities.
Putnins M; Androulakis IP
Crit Rev Biomed Eng; 2019; 47(6):473-488. PubMed ID: 32421972
[TBL] [Abstract][Full Text] [Related]
40. Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study.
Klinke DJ
J Immunother Cancer; 2015; 3():27. PubMed ID: 26082838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
